A Phase 1/2 interventional study of CM313 2 mg/kg and CM313 4 mg/kg in Systemic Lupus Erythematosus, sponsored by Keymed Biosciences Co.Ltd. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-20.
Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study of CM313 in subjects with systemic lupus erythematosus
This is a multi-center, randomed, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, Pharmacokinetics and preliminary anti-tumor activity.
About 40 patients who meet eligibility criteria will be randomized 4:1 to receive either CM313 or matched placebo, intravenous infusion.
The treatment period includes single dosing and multiple dosing period, in which CM313 and placebo will be adminitrated intravenously, once every 1 week.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
This study's planned enrollment of 40 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Browse Lupus Erythematosus, Systemic studies →Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once 1 week, intravenous infusion.
Biological: CM313 2 mg/kg
Once 1 week, intravenous infusion.
Biological: CM313 4 mg/kg
Once 1 week, intravenous infusion.
Biological: CM313 8 mg/kg
Once 1 week, intravenous infusion.
Biological: CM313 16 mg/kg
Once 1 week, intravenous infusion.
Biological: Placebo
Drug page: Lumrotatug
Once 1 week, intravenous infusion.
Drug page: Lumrotatug
Once 1 week, intravenous infusion.
Drug page: Lumrotatug
Once 1 week, intravenous infusion.
Drug page: Lumrotatug
Once 1 week, intravenous infusion.
Once 1 week, intravenous infusion.
Incidence of treatment-emergent adverse events (TEAEs).
Safety parameters
Time frame: Baseline up to Day 113
No study locations are listed for this record.
Start is estimated for Oct 2022; primary completion for Oct 2023, 12 months later.
Of 37 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumrotatug
Lupus Erythematosus, Systemic →